Market Movers (8-K)
See all →Whitehawk Therapeutics announced Q2 2026 results, highlighting continued enrollment in Phase 1 trials for HWK-007 and HWK-016, with HWK-206 initiation on track for Q3 2026, and an extended cash runway into 2H 2028.
Capital raise
Whitehawk Therapeutics shareholders approved the election of three directors and ratified the appointment of BDO USA, P.C. as auditor.
Whitehawk Therapeutics has secured an option agreement with Hangzhou DAC to access the CPT113 linker-payload for up to five new antibody drug conjugate programs.
Capital raise
Whitehawk Therapeutics announced a $87.5 million private placement equity financing to advance its oncology therapeutics pipeline.
Capital raise
Whitehawk Therapeutics reported Q1 2026 financial results, highlighting ongoing Phase 1 trials and a strong cash position extending into 2028.
Whitehawk Therapeutics announced its full-year 2025 financial results, highlighting active Phase 1 trials for two ADC programs and a strong cash position expected to fund operations into 2028.
Worse than expected
Quarterly Earnings (10-Q)
See all →Whitehawk Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $22.2 million and a strategic shift towards antibody-drug conjugates (ADCs).
Worse than expected
Capital raise
Whitehawk Therapeutics, Inc. reported a strategic pivot to its preclinical antibody-drug conjugate pipeline following the divestiture of its FYARRO business, significantly improving its cash position and reducing its accumulated deficit.
Better than expected
Capital raise
Whitehawk Therapeutics completed the divestiture of its FYARRO business and secured significant financing to advance its new preclinical antibody-drug conjugate pipeline.
Better than expected
Capital raise
10-Q: Whitehawk Therapeutics Reports Q1 2025 Results, Fueled by FYARRO Divestiture and New ADC Focus
Whitehawk Therapeutics reports a profitable Q1 2025 driven by the sale of its FYARRO business, shifting focus to preclinical ADC therapies.
Better than expected
Aadi Bioscience reports Q3 results, halts a key clinical trial, and initiates a strategic review to maximize shareholder value.
Worse than expected
Delay expected
Capital raise
Aadi Bioscience's Q2 2024 results show a slight decrease in revenue compared to the same period last year, alongside ongoing clinical development and strategic adjustments.
Worse than expected
Capital raise
Annual Reports (10-K)
Whitehawk Therapeutics divests its FYARRO business to focus on developing a portfolio of antibody-drug conjugates (ADCs) targeting various cancers.
Aadi Bioscience's recent SEC filing outlines the company's common stock details, preferred stock authorization, pre-funded warrants, and anti-takeover provisions.
Insider Trading (Form 4)
See all →Anupam Dalal, a Director of Aadi Bioscience, Inc., reported multiple transactions in common stock on May 14, 2026.
Director Zhao Baiteng was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.
Director Emma Reeve was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.
Director Richard E. Maroun was granted 38,040 stock options in Whitehawk Therapeutics, Inc. as part of an equity incentive plan.
Director Mohammad Hirmand of Whitehawk Therapeutics, Inc. was granted 38,040 stock options with an exercise price of $4.16.
Director Neil Desai was granted 38,040 stock options in Whitehawk Therapeutics, Inc. as part of an equity incentive plan.
Proxy Statements (Def-14A)
See all →Whitehawk Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
Capital raise
WhiteHawk Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.
Whitehawk Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.
DEFA14A: Aadi Bioscience to Sell FYARRO, In-License ADC Portfolio, and Secure $100 Million PIPE Financing
Aadi Bioscience is urging stockholders to vote in favor of proposals to sell FYARRO, in-license antibody drug conjugates (ADCs), and secure a $100 million private investment to transform the company and maximize shareholder value.
Capital raise
Aadi Bioscience appoints David Dornan as Chief Scientific Officer to advance its newly in-licensed ADC portfolio, coinciding with strategic moves including the sale of FYARRO and a private placement financing.
Capital raise
Aadi Bioscience is seeking stockholder approval for the sale of FYARRO to Kaken Pharmaceuticals for $100 million and a $100 million PIPE financing to support the in-licensing of an ADC portfolio.
Capital raise
Schedule 13D - Activist Investments
See all →Acuta Capital Partners and Anupam Dalal have reported a 9% beneficial ownership stake in Whitehawk Therapeutics following a private placement.
Capital raise
Avoro Capital Advisors disclosed a significant investment in Whitehawk Therapeutics through a $25 million private placement.
Capital raise
Neil Desai's beneficial ownership in Aadi Bioscience, Inc. has fallen to 4.9% after the company completed a private placement (PIPE) financing, issuing 21.6 million new shares.
Capital raise
SCHEDULE 13D/A: Shareholder Criticizes Aadi Bioscience Board for Rejecting Superior Buyout Offer and Pursuing Dilutive Financing
A significant shareholder, BML Investment Partners, L.P. and Braden M. Leonard, has reduced its stake in Aadi Bioscience, Inc. after criticizing the company's Board for rejecting a buyout offer of over $5 per share in favor of a dilutive $2.40 per share PIPE financing and a risky pre-clinical asset acquisition.
Worse than expected
Delay expected
Capital raise
SCHEDULE 13D/A: Avoro Entities and Behzad Aghazadeh Boost Stake in Aadi Bioscience to 19.99% Following PIPE Financing
Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have increased their beneficial ownership in Aadi Bioscience, Inc. to 19.99% of outstanding common stock following the closing of the 2024 PIPE Financing.
Capital raise
SCHEDULE 13D/A: Activist Investor Opposes Aadi Bioscience's Strategic Shift, Citing Rejected Acquisition Offer and Shareholder Dilution
An activist investor group, BML Investment Partners, L.P. and Braden M. Leonard, has filed an amended Schedule 13D, publicly opposing Aadi Bioscience, Inc.'s proposed strategic transactions, including an asset sale and significant share dilution, in favor of a previously rejected acquisition offer.
Worse than expected
Capital raise
Schedule 13G - Passive Investments
See all →OrbiMed Advisors LLC and OrbiMed Genesis GP LLC have jointly reported beneficial ownership of 7.3% of Whitehawk Therapeutics, Inc. common stock as of June 30, 2026.
Coastlands Capital LP and its affiliates have reported a 5.98% beneficial ownership stake in Whitehawk Therapeutics, Inc. common stock.
OrbiMed Advisors LLC and OrbiMed Genesis GP LLC have jointly disclosed a passive beneficial ownership of 8.9% in Whitehawk Therapeutics, Inc., totaling 4,166,000 shares of common stock.
Point72 Asset Management and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 5,087 shares, representing 0% of Whitehawk Therapeutics, Inc.'s common stock.
Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have jointly disclosed beneficial ownership of up to 9.99% of Aadi Bioscience, Inc.'s common stock.
SCHEDULE 13G: Ally Bridge Group and Affiliates Disclose Significant Passive Stake in Aadi Bioscience
Ally Bridge Group and its affiliated entities, including Mr. Fan Yu, have filed a Schedule 13G disclosing their passive beneficial ownership of Aadi Bioscience, Inc. common stock, with Mr. Fan Yu holding an aggregate of 6.3%.